Abstract
Purpose: Trastuzumab deruxtecan (T-DXd) has been available since April 2021 via the Cancer Drugs Fund for patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more anti-HER2 therapies, following the results of the phase II DESTINY-Breast01 trial [1]. We examined our local T-DXd use and associated clinical outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
